MX2012005497A - Tivozanib y temsirolimus en combinacion. - Google Patents
Tivozanib y temsirolimus en combinacion.Info
- Publication number
- MX2012005497A MX2012005497A MX2012005497A MX2012005497A MX2012005497A MX 2012005497 A MX2012005497 A MX 2012005497A MX 2012005497 A MX2012005497 A MX 2012005497A MX 2012005497 A MX2012005497 A MX 2012005497A MX 2012005497 A MX2012005497 A MX 2012005497A
- Authority
- MX
- Mexico
- Prior art keywords
- tivozanib
- dose
- temsirolimus
- combination
- per day
- Prior art date
Links
- SPMVMDHWKHCIDT-UHFFFAOYSA-N 1-[2-chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-3-(5-methyl-3-isoxazolyl)urea Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC=1C=C(C)ON=1 SPMVMDHWKHCIDT-UHFFFAOYSA-N 0.000 title abstract 4
- 229960000940 tivozanib Drugs 0.000 title abstract 4
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 title abstract 2
- 229960000235 temsirolimus Drugs 0.000 title abstract 2
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000006265 Renal cell carcinoma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se describe un método para tratar un tumor en un paciente humano. El método comprende co-administrar al paciente: (a) una dosis de 1.5 mg de tivozanib por día; y (b) una dosis de 25 mg de temsirolimus por semana. En algunas modalidades de la invención, el tivozanib se adininistra en un programa de repetición de una dosis por día durante tres semanas, seguido de una semana sin administración de tivozanib. El método descrito es particularmente adecuado para el tratamiento de carcinoma de células renales.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26125209P | 2009-11-13 | 2009-11-13 | |
| US12/856,414 US7998973B2 (en) | 2009-11-13 | 2010-08-13 | Tivozanib and temsirolimus in combination |
| PCT/US2010/056372 WO2011060162A1 (en) | 2009-11-13 | 2010-11-11 | Tivozanib and temsirolimus in combination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012005497A true MX2012005497A (es) | 2012-07-03 |
Family
ID=43992030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012005497A MX2012005497A (es) | 2009-11-13 | 2010-11-11 | Tivozanib y temsirolimus en combinacion. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7998973B2 (es) |
| EP (1) | EP2498606A4 (es) |
| JP (1) | JP2013510866A (es) |
| KR (1) | KR20120104574A (es) |
| CN (1) | CN102781238A (es) |
| BR (1) | BR112012011316A2 (es) |
| CA (1) | CA2780495A1 (es) |
| MX (1) | MX2012005497A (es) |
| RU (1) | RU2012123970A (es) |
| WO (1) | WO2011060162A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9642918B2 (en) * | 2011-12-16 | 2017-05-09 | Pfizer Inc. | Combination of inotuzumab ozogamicin and torisel for the treatment of cancer |
| CA2863188A1 (en) | 2012-02-02 | 2013-08-08 | Acceleron Pharma Inc. | Alk1 antagonists and their uses in treating renal cell carcinoma |
| EA202191273A1 (ru) * | 2018-11-05 | 2021-09-15 | Авео Фармасьютикалз, Инк. | Применение тивозаниба для лечения субъектов с рефрактерным раком |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL209822B1 (pl) | 2001-04-27 | 2011-10-31 | Kirin Pharma Kk | Pochodna chinoliny lub chinazoliny, zawierająca ją kompozycja farmaceutyczna i zastosowanie |
| US20060094674A1 (en) | 2002-07-05 | 2006-05-04 | Neel Benjamin G | Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms |
| JP3763414B2 (ja) | 2002-10-21 | 2006-04-05 | 麒麟麦酒株式会社 | Ｎ−｛２−クロロ−４−［（６，７−ジメトキシ−４−キノリル）オキシ］フェニル｝−ｎ’−（５−メチル−３−イソキサゾリル）ウレアの塩の結晶形 |
| AR058505A1 (es) * | 2005-11-04 | 2008-02-06 | Wyeth Corp | Combinaciones antineoplasicas de temsirolimus y malato de sunitinib |
-
2010
- 2010-08-13 US US12/856,414 patent/US7998973B2/en not_active Expired - Fee Related
- 2010-11-11 BR BR112012011316A patent/BR112012011316A2/pt not_active IP Right Cessation
- 2010-11-11 MX MX2012005497A patent/MX2012005497A/es not_active Application Discontinuation
- 2010-11-11 EP EP10830726.5A patent/EP2498606A4/en not_active Withdrawn
- 2010-11-11 CA CA2780495A patent/CA2780495A1/en not_active Abandoned
- 2010-11-11 WO PCT/US2010/056372 patent/WO2011060162A1/en not_active Ceased
- 2010-11-11 JP JP2012538979A patent/JP2013510866A/ja not_active Withdrawn
- 2010-11-11 KR KR1020127015135A patent/KR20120104574A/ko not_active Withdrawn
- 2010-11-11 RU RU2012123970/15A patent/RU2012123970A/ru unknown
- 2010-11-11 CN CN2010800514429A patent/CN102781238A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2498606A4 (en) | 2013-05-15 |
| US20110118297A1 (en) | 2011-05-19 |
| JP2013510866A (ja) | 2013-03-28 |
| BR112012011316A2 (pt) | 2015-10-06 |
| CA2780495A1 (en) | 2011-05-19 |
| US7998973B2 (en) | 2011-08-16 |
| RU2012123970A (ru) | 2013-12-20 |
| KR20120104574A (ko) | 2012-09-21 |
| CN102781238A (zh) | 2012-11-14 |
| WO2011060162A1 (en) | 2011-05-19 |
| EP2498606A1 (en) | 2012-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ597378A (en) | Treatment of multiple sclerosis with laquinimod | |
| RU2013148721A (ru) | Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения | |
| PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| UA105644C2 (uk) | Способи лікування легеневих порушень складами ліпосомального амікацину | |
| IN2012DN03172A (es) | ||
| MY173215A (en) | Acetylcysteine compositions and methods of use thereof | |
| NZ700824A (en) | Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients | |
| NZ591525A (en) | Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin | |
| UA105191C2 (ru) | Лечение пирфенидоном пациентов с атипической функцией печени | |
| MX2016011333A (es) | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. | |
| MX2009003532A (es) | Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina. | |
| MY158929A (en) | Pharmaceutical combination | |
| MX2007004955A (es) | Metodo de tratar cancer con formulaciones de compeusto de platino a base de lipido administradas intraperitonealmente. | |
| MX2013003523A (es) | Composicion farmaceutica de dosis baja. | |
| MX2012005497A (es) | Tivozanib y temsirolimus en combinacion. | |
| PH12021552977A1 (en) | Methods of treating urinary system cancers | |
| JOP20170044B1 (ar) | تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو | |
| MX2010006310A (es) | O-desmetil-venlafaxina para el tratamiento de transtorno depresivo mayor. | |
| WO2020234431A8 (en) | Treatment of hyperammonemia in patients with renal insufficiency | |
| UA45323U (ru) | Способ коррекции дислипидемии у больных подагрой | |
| MX2020001217A (es) | Metodos de tratamiento de sintomas de gastroparesia usando velusetrag. | |
| PH12015500915A1 (en) | Bremelanotide therapy for female sexual dysfunction | |
| WO2007067753A3 (en) | Methods of reducing side effects in cancer therapy | |
| UA47304U (ru) | Способ лечения хронических рецидивирующих пиодермий | |
| UA48009U (ru) | Способ лечения пациентов с дисфункцией сфинктера одди |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |